Video summary

#DestinationRural Grand Rounds - Gender Affirming Care

Main summary

Key takeaways

Educational

Main ideas / concepts conveyed

  • Gender-affirming care in rural practice: The talk focuses on how a rural GP can approach gender-affirming care using a practical, guideline-based framework across multiple visits/stages, emphasizing safety, communication, and holistic care.
  • Case-based learning (the “RE” scenario): A registrar considers how to conduct initial assessment and subsequent management for a patient seeking feminizing gender affirmation.
  • Five-stage model of medical affirmation: Care is structured into stages that progressively move from introductory discussions to initiation of hormones and then monitoring/ongoing support.
  • Guideline-driven clinical approach: Two guideline resources are highlighted as key references:
    • AUSPATH: informed consent standards for gender-affirming hormone therapy.
    • Equinox Clinic (Melbourne): protocols for initiation of hormone therapy for trans and gender diverse patients.
  • Holistic medical approach: Medical gender affirmation includes not only hormones, but also mental health, sexual health risk, and appropriate baseline/ongoing screening.

Methodology / instructional framework (detailed)

1) Set up the care pathway using a staged model (5 stages)

Stage 1: Introductory consult (service introduction + establishing safety)

Goals

  • Affirm the patient’s gender identity.
  • Ensure the patient feels safe in the practice.
  • Address relevant cultural needs.

Communication methodology

  • Use the patient’s preferred language for anatomy (ask what terms they like).
  • Stay non-confrontational and neutral (e.g., say “genitals” rather than explicit terms).

Assess relevant context

  • Determine the patient’s gender goals (social, medical, surgical).
  • Determine sexuality/sexual behaviors when relevant (as it affects later care).

Revisit goals over time

  • Do not assume one-size-fits-all gender affirmation needs.

Stage 2: Initial medical review (history + contraindications + baseline tests)

History taking

  • Obtain complete medical history to identify contraindications to hormones.
  • Consider contraindications relevant to the hormone route being used (e.g., feminizing typically involves estrogen; compare contraindications to those used in menopause hormone therapy/oral contraceptives).

Key contraindications discussed for estrogen (examples)

  • Uncontrolled/deranged liver disease.
  • Current or past venous thromboembolism history.
  • (Emphasized that these align broadly with menopause hormone therapy/oral contraceptive principles.)

Baseline investigations

  • Full blood count (FBC/FBC).
  • Biochemistry including LFTs.
  • Hormone profile (including measures used to guide dosing/monitoring).
  • Metabolic risk assessment (lipids, etc., as appropriate).

Age/sex-appropriate screening

  • Example: prostate screening considerations as relevant.

Fertility goals

  • Explicitly ask about fertility preservation desires early.
  • Emphasized that fertility preservation may require de-transition or interruption later, so discuss early and revisit.

Monitor for patient-specific factors

  • Mental health, medication history, and relevant sexual health needs are integrated into assessment.

Stage 3: Counseling and education (goals + expectations + referrals)

Re-explore patient goals

  • Clarify which changes the patient wants (facial/voice/skin/breast development/body hair, etc.).

Perform relevant physical checks

  • Mentioned minimum checks such as BMI and blood pressure (because metabolic risk changes with hormones).

Discuss what hormone therapy will realistically do

  • Use patient-facing resources to guide expectation timelines and early vs later effects.

Arrange referrals as needed

  • Example given for voice goals:
    • ENT/plastics (e.g., for Adam’s apple-related concerns).
    • Speech pathology (including trans-affirming voice therapy, sometimes via AusPATH-listed clinicians).
    • Creative rural alternatives: voice/singing coaches for dialect coaching (when appropriate).

Stage 4: Hormone initiation (prescribing + regimen selection)

Use accessible tools for dosing guidance

  • The speaker highlights TransHub as interactive and patient-facing, including “Hormones 101” and condition-specific regimen information.

Example regimen logic in the case

  • Estrogen start: estradiol 2 mg daily, with planned increases every ~3 months to achieve clinical and biochemical changes.
  • Discuss progesterone carefully:
    • Not commonly used; evidence limited; presented as an “add-on” topic for questions rather than routine initiation.
  • Anti-androgen use:
    • Example: spironolactone suggested and later monitoring considered (e.g., potassium).

Forms and administration options

  • Estrogen route options discussed: pills, patches, gels, injections, implants.
  • Implant was discussed as a patient interest but not initiated in the case due to device availability.

Telehealth specialist support

  • Emphasized that rural practitioners may rely on endocrinology/telehealth specialists for rapid review and dosing support.

Stage 5: Monitoring and ongoing support (follow-up + safety + sexual health)

Follow-up timing

  • Preferred: 2–4 weeks after substantial initiation (to ensure access/adherence and early issues).
  • Guidelines approach: every 3 months for the first year, then at least 12-monthly.

Monitoring purpose

  • Check response in both clinical effect and biochemical targets.
  • Detect side effects and manage risks.

Example monitoring elements

  • Repeat hormone levels (e.g., testosterone suppression, estradiol into target range).
  • Prolactin consideration (feedback effects of estrogen).
  • Potassium monitoring if on spironolactone.
  • Cardiovascular/metabolic risk markers:
    • Periodic blood pressure/BMI, lipids; fasting glucose considered depending on patient factors.

Pathology ordering practical tip

  • When requesting estrogen/progesterone tests for patients assigned male at birth, specify context on the lab request to avoid “undetectable” reporting that doesn’t help dosing assessment.

Mental health integration

  • Expect possible improvement in mental health as gender dysphoria is affirmed (but continue to monitor).

Sexual health considerations

  • High trans/non-binary risk for STI and blood-borne viruses was emphasized.
  • Discuss sexual partners/behaviors and consider prevention strategies (e.g., PrEP) where appropriate.

Adherence and rural barriers

  • Follow-up loss can occur; guidance on prescribing logistics:
    • Do not give indefinite hormone repeats without follow-up planning; prescribe enough to reach the next review with an explicit appointment expectation.

End goal of stage 5

  • Keep the patient safe, connected, and supported as they explore next steps beyond hormone initiation.

2) Practical resources repeatedly recommended

  • TransHub

    • Used to guide conversations and patient education.
    • Includes domains: social affirmation, medical affirmation, legal affirmation.
    • Provides interactive, approachable content for hormone initiation (“Hormones 101” and hormone-specific sections).

  • AUSPATH guideline (Ozpath)

    • For practice/informed consent standards regarding hormone therapy.

  • Equinox Clinic protocols

    • For initiation practices in trans and gender diverse patients.

3) Guidance on social/administrative affirmation (non-medical but medically important)

  • Social affirmation is framed as highly significant

    • Outcomes include practical administrative changes (e.g., Medicare name updates) that can prevent ongoing distress and reminders of misalignment.

  • Medication and care depend on documentation

    • Medicare and pathology scripts can reflect the patient’s misalignment if not corrected, creating barriers.

4) Prescribing scope tips and legal/clinical cautions mentioned

Adults

  • Estrogen can be prescribed without specialist permission (though referral may be used).
  • Testosterone often requires referral.

Adolescents/children

  • Requires specialist assistance and additional psychological evaluation.
  • A legal change was described as making consent require both caregivers/parents (previously less restrictive in many circumstances).

Clinical “flags” to consider before proceeding

  • High mental health illness burden where capacity to consent is questionable (e.g., severe depression, ongoing suicidality, poor insight).
  • Significant neurodiversity affecting insight/capacity.

Surgical affirmation and psychiatric review

  • For surgery in adult patients with gender dysphoria and capacity, psychiatric review is not necessarily required if the care plan appropriately supports dysphoria alleviation.
  • If uncertainty exists about understanding/permanent nature/implications, assess capacity/insight and consider further evaluation.

5) Hormone dosing philosophy (estrogen vs menopause)

  • Menopause hormone therapy: usually aims for the lowest effective dose to relieve symptoms.
  • Gender-affirming estrogen: often uses higher/more maximal dosing, since treatment is intended to counteract existing endogenous masculinizing hormone effects.

Speakers / sources featured (identified)

Speakers

  • Dr Dan Wilson (speaker/presenter)
  • Marion (host/moderator; asks/acknowledges, manages Q&A flow)
  • Audience participants (named as called out during interactive segments):
    • Sally
    • Luila
    • Rebecca (appears multiple times)
    • Additional audience members who asked questions in the Q&A (no names given in subtitles)

Sources / organizations referenced

  • AUSPATH / Ozpath (guideline: informed consent standards for gender-affirming hormone therapy)
  • Equinox Clinic (Melbourne) (protocols for initiation of hormone therapy)
  • TransHub (interactive education resources including social/legal/medical domains)
  • Shine SA (referenced as a sexual health poster resource website/company)
  • Doctors in Training group of the Australian Medical Association (AMA) (mentioned at close as the organizing community; specific named entity not otherwise elaborated)

Original video